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1. Introduction 
The role played by sialic acids in determining the 
antigenic specificities of the cell surface is still a 
matter of discussion. It is known that sialic acids are 
involved in determining the human blood group M and 
N specificities [l-3] : neuraminidase treated erythro- 
cytes, other than very briefly, lose both M and N spe- 
cificities, while a very mild desialylation converts M 
antigen into N antigen [4-71. Recently the molecular 
structure of M and N oligosaccharides has been estab- 
lished, and it has been found that M differs from N 
substance only in an extra sialic acid residue that 
covers the terminal galactose of the N determinant 
PI. 
Sialic acids are also involved in erythrocyte antigens 
such as the F antigen [9] and the Prr and the Prs 
system [lo]. 
On the other hand, sialic acids seem to exert a 
peculiar negative role in masking surface antigens 
expressed on cell membrane other than erythrocytes. 
On tumor cell surface, tumor specific antigens seem 
to be masked by neuraminidase-sensitive sialic acid 
residues [ 1 l- 131. Removal of sialic acids increases 
immunogenicity also of normal cells [ 14- 161. More- 
over, neuraminidase treatment has the same effect on 
orosomucoid, a soluble sialoglycoprotein antigen [ 17, 
181. 
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In the present paper the role of sialic acids in the 
immunological properties of glycoproteins solubilized 
from the plasma membrane of a mouse plasmacell 
tumor was investigated. 
2. Materials and methods 
MOPC-460 plasmacytoma cells were grown in vivo, 
in syngeneic Balb/C mice, by serial subcutaneous 
transplantations. For immunofluorescence experi- 
ments, cells were cultured in suspension, in Eagle’s 
MEM Spinner, supplemented with 10% horse serum. 
Membrane fractions were prepared on discontinuous 
sucrose gradients, as previously described in detail 
[ 191. Membranes were solubilized in 3 M potassium 
chloride [20], 10 mM phosphate buffer, pH 7.2, by 
vigorous stirring overnight at 4°C. The supernatant 
harvested after centrifugation at 105 000 g for 90 
min, was dialyzed against phosphate buffered saline 
(PBS) and recentrifuged. This material was designated 
as solubilized membrane antigens (SMA). 
Protein concentration of SMAs was determined by 
the Lowry’s method; sialic acids were quantitated by 
the Warren’s method using thiobarbituric acid assay 
WI. 
Desialylation of SMAs was performed by Vibrio 
Cholerae neuraminidase (Koch Light Laboratories) 
repurified by affinity chromatography on insolubilized 
p-amino-phenyl-N-oxamic acid, following the method 
described by Cuatrecasas [22]. SMAs were incubated 
with 15 U of neuraminidase/mg SMA protein, in 0.1 M 
sodium acetate buffer, pH 5.2, 3 mM CaClz for 3 hr 
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at 37°C. Endogenous proteolytic activity was inhibited 
by addition of tosyl-phenylalanyl-chloromethyl- 
ketone (TPCK) and of tosyl-lysyl-chloromethyl-ketone 
(TLCK) to the final concentration of 30 PM and 200 PM 
respectively. Control samples were incubated under the 
same conditions, but neuraminidase was added after 
incubation. For immunofluorescence experiments, 
10s tumor cells were washed and incubated at 37°C 
for 30 min in serum free medium with 100 U of 
neuraminidase, 3 mM CaC12, at pH 7.0. This treat- 
ment did not affect cell viability that was > 90%, as 
assessed by Trypan blue exclusion test. Rabbit-anti- 
SMA antisera were obtained by immunizing New 
Zealand rabbits with three monthly-spaced subcutane- 
ous injections of 6 mg of SMA protein, emulsified 
1: 1 in Freund’s complete adjuvant. 
Precipitating reactions in tubes were performed by 
the micromethod described by Maurer [23] : all steps 
were performed at 4°C in order to prevent the 
activity of neuraminidase and endogenous proteases. 
Immunofluorescence experiments were performed 
as follows: 1 O7 neuraminidase-treated or untreated 
MOPC-460 cells were incubated for 10 min at 37°C 
and for 15 min at 0°C with 0.2 ml of the appropriately 
diluted rabbit antiserum. After repeated washings with 
complete culture medium, cells were stained for 
30 min at 0°C with the immunoglobulin fraction of a 
goat anti-rabbit L chain antiserum, FITC labelled 
[24]. Samples were examined with a Leitz Ortholux 
fluorescence microscope equipped with incident 
light and immersion objectives. 
3. Results and discussion 
Neuraminidase released from SMAs about 60% of 
the total protein-bound sialic acids. 
Immune precipitation in tubes of desialylated SMA 
and of control SMA against rabbit anti native SMA 
antiserum gave rather regular curves (fig. 1). The point 
of maximal precipitation obtained with controlSMA 
was reached when about 50 pg of protein were added 
to the antiserum. When the same amount of desialyl- 
ated SMA was reacted with the antiserum, the amount 
of precipitate was reduced by about 10-l 5%. More- 
over, the curve obtained with the desialylated SMA 
showed a broader plateau and the point of maximal 
precipitation was reached only at concentrations close 
352 
r 
25 50 75 100 
pg SMA added 
Fig.1. The effect of neuraminidase treatment on the precipita- 
tion of solubilized membrane antigens by specific rabbit 
antibodies. Increasing amounts of antigens were added to 
constant aliquots of antiserum. (a-): desialylated mem- 
brane antigens; (04): control membrane antigens. Vertical 
bars represent the standard error. 
to 80 pg protein. These points were constantly 10% 
lower than those obtained with the controlSMA. 
These findings suggested that neuraminidase treat- 
ment of SMA led to the loss of some antigenic 
determinants expressed by membrane glycoproteins. 
A set of immunofluorescence experiments was per- 
formed to check whether this hypothesis was consistent 
also for the membrane glycoproteins exposed on the 
surface of living cells. 
The antiSMA antiserum was tested by indirect 
immunofluorescence with living MOPC-460 cells. At 
dilutions of 1: 50 100% of the cells were positive. The 
fluorescence was intense and restricted to the cell 
surface, that was homogeneously stained. This anti- 
serum, incubated three times, sequentially, with un- 
treated cells (0.25 ml of packed cells/O.45 ml of diluted 
serum in ice) was completely adsorbed (table 1). 
The antiserum was then adsorbed with desizlylated 
cells. Neuraminidase removed 55% of the total sialic 
acids from living MOPC-460 cells. Since the enzyme 
does not enter living cells [25], and if the general 
assumption that the surface sialic acids account for 
about 70% of the total is valid also for plasmacells, 
this result means that in our conditions neuraminidase 
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Table 1 
Adsorption of antiserum against solubilized membrane antigens by 
desialylated MOPC-460 plasmacytoma cells 
March 1975 
Cells Antiserum 
Cells showing surface 
fluorescence** 
% of the total S.E.M. 
Untreated Unadsorbed 100 0 
Untreated Adsorbed with untreated cells 0 0 
Untreated Adsorbed with desialylated cells 50.9* c 3.7 
Desialylated Adsorbed with desialylated cells 5.1” f 0.9 
* p < 0.001 (calculated by x2 test). 
** Cells were incubated with the appropriately diluted (1:50) rabbit antiserum 
and stained with FITC-labelled goat anti-rabbit L chain antibodies. 
removed about 80% of the sialic acids exposed on the 
cell surface. 
At dilutions of 1: 50 the antiserum adsorbed with 
desialylated cells still reacted with 50% of the untreated 
cells (table 1). In this case the fluorescence was definite 
but faint and localized in few spots, irregularly distrib- 
uted over the cell surface. When tested against desialyl- 
ated cells, the percentage of positive cells was 
drastically reduced to about 5% (table 1). 
This result was consistent with the data obtained 
from immune precipitation experiments, suggesting 
the involvement of sialic acids in some antigenic deter- 
minants of membrane glycoproteins. Moreover it 
showed that these sialic acid-dependent antigenic 
determinants, or at least some of them, are exposed on 
the surface.of intact cells in physiological conditions, 
when membrane glycoproteins are in their native 
1 configuration. 
How sialic acid molecules contribute to antigenic 
determinants of glycoproteins cannot be predicted. 
Sialic acids may be directly part of the determinants 
and, thus, directly interact with the active site of the 
corresponding antibody molecules. Alternatively, 
sialic acid residues may be close to some determinants, 
but, being highly hydrophilic, are necessary to pull 
these determinants to the outer surface of the antigen 
molecule. Finally, sialic acid residues may only be 
involved in keeping sialoglycoprotein antigens in a 
given tertiary structure; desialylation of these antigens 
would lead to the loss of determinants of conforma- 
tional nature. 
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